A Study to Evaluate 5 μg/kg Tbo-filgrastim in Infants, Children and Adolescents With Solid Tumors Without Bone Marrow Involvement

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

May 12, 2015

Primary Completion Date

April 4, 2017

Study Completion Date

April 4, 2017

Conditions
Neutropenia
Interventions
DRUG

tbo-filgrastim

5 μg/kg

Trial Locations (33)

1089

Teva Investigational Site 51186, Budapest

1094

Teva Investigational Site 51185, Budapest

6725

Teva Investigational Site 51184, Szeged

9010

Teva Investigational Site 59105, Varna

10000

Teva Investigational Site 60014, Zagreb

Teva Investigational Site 60016, Zagreb

10595

Teva Investigational Site 12959, Valhalla

15257

Teva Investigational Site 59104, Sofia

21029

Teva Investigational Site 58146, Vinnytsia

Teva Investigational Site 58149, Vinnytsia

39216

Teva Investigational Site 12954, Jackson

43205

Teva Investigational Site 12960, Columbus

51000

Teva Investigational Site 60015, Rijeka

61070

Teva Investigational Site 58147, Kharkiv

77030

Teva Investigational Site 12957, Houston

79035

Teva Investigational Site 58148, Lviv

89109

Teva Investigational Site 12953, Las Vegas

90024

Teva Investigational Site 12951, Los Angeles

90806

Teva Investigational Site 12958, Long Beach

117198

Teva Investigational Site 50284, Moscow

197110

Teva Investigational Site 50280, Saint Petersburg

300383

Teva Investigational Site 52065, Timișoara

350007

Teva Investigational Site 50281, Krasnodar

400015

Teva Investigational Site 52064, Cluj-Napoca, Cluj

400138

Teva Investigational Site 50283, Volgograd

454076

Teva Investigational Site 50282, Chelyabinsk

80-952

Teva Investigational Site 53249, Gdansk

20-093

Teva Investigational Site 53248, Lublin

01-211

Teva Investigational Site 53245, Warsaw

04-730

Teva Investigational Site 53246, Warsaw

50-556

Teva Investigational Site 53247, Wroclaw

022328

Teva Investigational Site 52063, Bucharest

03022

Teva Investigational Site 58145, Kyiv

All Listed Sponsors
lead

Teva Branded Pharmaceutical Products R&D, Inc.

INDUSTRY

NCT02190721 - A Study to Evaluate 5 μg/kg Tbo-filgrastim in Infants, Children and Adolescents With Solid Tumors Without Bone Marrow Involvement | Biotech Hunter | Biotech Hunter